STOCK TITAN

Ocular Therapeutix (OCUL) director receives 14,000 RSUs and 44,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Hong Seung Suh reported acquisition or exercise transactions in this Form 4 filing.

Ocular Therapeutix director Seung Suh Hong received new equity awards as part of board compensation. He was granted 14,000 restricted stock units, each representing one future share of common stock, and 44,000 stock options to buy common shares at $8.74 per share.

The awards vest in full on the first anniversary of the June 10, 2026 grant date, or earlier immediately before the next annual stockholder meeting, as long as he continues serving on the board. After the grant, he directly holds 60,933 common shares and 44,000 options.

Positive

  • None.

Negative

  • None.
Insider Hong Seung Suh
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 44,000 $0.00 --
Grant/Award Common Stock 14,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 44,000 shares (Direct, null); Common Stock — 60,933 shares (Direct, null)
Footnotes (1)
  1. On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
Restricted stock units granted 14,000 RSUs Grant to director on June 10, 2026
Stock options granted 44,000 options Director equity award on June 10, 2026
Option exercise price $8.74 per share Stock Option (Right to Buy)
Option expiration June 9, 2036 End of option term
Common shares after grant 60,933 shares Direct holdings following RSU award
Underlying option shares 44,000 shares Common stock underlying options
restricted stock units financial
"the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2021 Stock Incentive Plan financial
"RSUs under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc."
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vesting financial
"the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion_or_exercise_price": "8.7400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hong Seung Suh

(Last)(First)(Middle)
C/O OCULAR THERAPEUTIX, INC.
14 CROSBY DRIVE, 3RD FLOOR

(Street)
BEDFORD MASSACHUSETTS 01730

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/10/2026A14,000(1)A$060,933D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$8.7406/10/2026A44,000 (2)06/09/2036Common Stock44,000$044,000D
Explanation of Responses:
1. On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
2. Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
/s/ Todd Anderman, Attorney-in-Fact for Seung Suh Hong06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Ocular Therapeutix (OCUL) director Seung Suh Hong receive?

He received 14,000 restricted stock units and 44,000 stock options. Each RSU equals one future common share, while each option allows purchase of one share at $8.74, subject to vesting conditions.

What are the vesting terms of the new OCUL RSUs and options for Hong?

Both the 14,000 RSUs and 44,000 options vest 100% after one year. Vesting occurs on the first anniversary of the June 10, 2026 grant or immediately before the next annual stockholder meeting, assuming continued board service.

What is the exercise price and expiration date of Hong’s OCUL stock options?

The 44,000 stock options have a fixed exercise price of $8.74 per share. They are scheduled to expire on June 9, 2036, giving a long window to exercise once vested, subject to plan terms.

How many OCUL shares does Seung Suh Hong hold after these grants?

After the award of 14,000 restricted stock units, he directly holds 60,933 common shares. In addition, he holds 44,000 stock options that, once vested and exercised, could convert into the same number of shares.

Are Hong’s new OCUL equity awards tied to a stock incentive plan?

Yes, the 14,000 restricted stock units were granted under Ocular Therapeutix’s 2021 Stock Incentive Plan, as amended. The options follow similar plan-based terms, including vesting conditions linked to continued board service and a defined expiration date.